51410 reder	a1	Kegisi
Drug	S	Schedule
Propiram (9649)	ī	
1–Methyl–4–phenyl–4–	i	
propionoxypiperidine (9661).		
1-(2-Phenylethyl)-4-phenyl-	I	
4acetoxypiperidine (9663). Tilidine (9750)	ı	
Para-Fluorofentanyl (9812)	i	
3-Methylfentanyl (9813)	1	
Alpha-Methylfentanyl (9814)	!	
Acetyl-alpha-methylfentanyl (9815).	ı	
Benzylfentanyl (9818)	ı	
Beta-Hydroxyfentanyl (9830)	1	
Beta-Hydroxy-3-methylfentanyl	ı	
(9831). Alpha-Methylthiofentanyl (9832)	ı	
3–Methylthiofentanyl (9833)	i	
Thenylfentanyl (9834)	1	
Thiofentanyl (9835)	1	
Amphetamine (1100) Methamphetamine (1105)	II II	
Phenmetrazine (1631)	ii	
Methylphenidate (1724)	Ш	
Amobarbital (2125)	II	
Pentobarbital (2270) Secobarbital (2315)	II II	
Glutethimide (2250)	ii	
Nabilone (7379)	Ш	
1-Phenylcylohexylamine (7460)	II	
Phencyclidine (7471)Phenylacetone (8501)	II II	
1-	ii	
Piperidinocyclohexanecarbonitr-		
ile (8603). Alphaprodine (9010)	Ш	
Anileridine (9020)	II	
Cocaine (9041)	II	
Codeine (9050)	II	
Etorphine HCL (9059)	ii	
Dihydrocodeine (9120)	Ш	
Oxycodone (9143)	II	
Hydromorphone (9150) Diphenoxylate (9170)	II II	
Benzoylecgonine (9180)	ii	
Ecgonine (9180)	Ш	
Ethylmorphine (9190)	II	
Hydrocodone (9193) Levomethorphan (9210)	II II	
Levorphanol (9220)	ii	
Isomethadone (9226)	Ш	
Meperidine (9230)	II	
Meperidine intermediate-A (9232) Meperidine intermediate-B (9233)	II II	
Meperidine intermediate-C (9234)	ii	
Metazocine (9240)	Ш	
Methadone (9250)	II	
Methadone intermediate (9254) Metopon (9260)	II II	
Morphine (9300)	ii	
Thebaine (9333)	Ш	
Dihydroetorphine (9934)	II	
Opium, raw (9600)	II II	
Opium powdered (9639)	ii	
Levo-alphacetylmethadol (9648)	II	
Oxymorphone (9652)	II	
Phenazocine (9715) Piminodine (9730)	II II	
Racemethorphan (9732)	ii	
Racemorphan (9733)	II	
Alfentanil (9737)Remifentanil (9739)	II II	
Sufentanii (9739)	II	
(-,)		

Drug	Schedule
Carfentanil (9743)	

The firm plans to manufacture small quantities of bulk material for use in reference standards.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel, (CCD) and must be filed no later than August 2, 2004.

Dated: May 18, 2004.

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04–12463 Filed 6–2–04; 8:45 am] **BILLING CODE 4410–09–M**

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated February 4, 2004, and published in the **Federal Register** on February 18, 2004, (69 FR 7655), Applied Science Labs, Division of Alltech Associates Inc., 2701 Carolean Industrial Drive, P.O. Box 440, State College, Pennsylvania 16801, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
2, 5-dimethoxy-4-(n)- propylthiophenethylamine (2C- T-7) (7348).	I
Alpha-methyltryptamine (AMT) (7432).	1
5-methoxy-N-, N-diisopropyltryptamine (5–MeO–DIPT) (7439).	I

The firm plans to manufacture small quantities of the listed controlled substances for reference standards.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code,

Section 823(a) and determined that the registration of Applied Science Labs to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Applied Science Labs to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed is granted.

Dated: May 21, 2004.

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04-12453 Filed 6-2-04; 8:45 am]

BILLING CODE 4410-09-M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 4, 2004, Applied Science Labs, Division of Alltech Associates Inc., 2701 Carolean Industrial Drive, State College, Pennsylvania 16801, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below.

Drug	Schedule
Methcathinone (1237)	1
N-Ethylamphetamine (1475)	1
N,N-Dimethylamphetamine (1480)	1
4-Methylaminorex (cis isomer) (1590).	1
Alpha-Ethyltryptamine (7249)	1
Lysergic acid diethylamide (7315)	1
2,5-dimethoxy-4(n)-	1
propylthiophenethylamine (2C-T-7) (7348).	
Mescaline (7381)	1
4-Bromo-2,5-	1
dimethoxyamphetamine (7391).	
4-Bromo-2,5-	1
dimethoxyphenethylamine (7392).	

Drug	Schedule
4-Methyl-2,5-	1
dimethoxyamphetamine (7395).	
2-5-Dimethoxy-4-	1
ethylamphetamine (7399).	
3,4-Methylenedioxyamphetamine (7400).	I
N-Hydroxy-3,4-	1
methylenedioxyamphetamine (7402).	
3,4-Methylenedioxy-N-	1
ethylamphetamine (7404).	
3,4-	1
Methylenedioxymethamphetam-ine (7405).	
Alpha-methyltryptamine (AMT) (7432).	1
Bufotenine (7433)	ı
Diethyltryptamine (7434)	1
Dimethyltryptamine (7435)	1
Psilocybin (7437)	1
Psilocyn (7438)	1
5-methxy-N,N-	I
diisopropyltryptamine (5-MeO-DIPT) (7439).	
N-Ethyl-1-phenylcyclohexylamine (7455).	I
1-(1-Phenylcyclohexyl)pyrrolidine	I
(PCPy) (7458).	
1[1-(2	I
Thienyl)cyclohexyl]piperidine (7470).	
Dihydromorphine (9145)	1
Normorphine (9313)	I I
Methamphetamine (1105)	
1-Phenylcylohexylamine (7460)	
Phencyclidine (7471)	II
Phenylacetone (8501)	II
1- Piperidinocyclohexanecarbonitr-	II
ile (8603).	
Cocaine (9041)	П
Codeine (9050)	ii
Dihydrocodeine (9120)	II
Benzoylecgonine (9180)	II
Ethylmorphine (9190)	II
Morphine (9300)	II
Noroxymorphone (9668)	II

The firm plans to manufacture small quantities of the listed controlled substances for reference standards.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than August 2, 2004.

Dated: May 18, 2004.

William I. Walker.

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04–12460 Filed 6–2–04; 8:45 am] BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 1, 2004, American Radiolabeled Chemicals, Inc., 101 Arc Drive, St. Louis, Missouri 63146, made application by renewal to the Drug Enforcment Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below.

Drug	Schedule
Gamma hydroxybutyric acid (2010).	1
Dimethyltryptamine (7435)	1
Dihydromorphine (9145)	1
Cocaine (9041)	II
Codeine (9050)	II
Hydromorphone (9150)	II
Benzoylecgonine (9180)	II
Ecgonine (9180)	II
Meperidine (9230)	II
Metazocine (9240)	II
Morphine (9300)	II
Oxymorphone (9652)	II

The firm plans to bulk manufacture small quantities of the listed controlled substances as radiolabeled compounds.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than August 2, 2004.

Dated: May 21, 2004.

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04–12467 Filed 6–2–04; 8:45 am] BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 17, 2004, Boehringer Ingelheim Chemicals Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below.

Drug	Schedule
Amphetamine (1100)	

The firm plans to manufacture the listed controlled substances for formulation into finished pharmaceuticals.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than August 2, 2004.

Dated: May 5, 2004.

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04–12461 Filed 6–2–04; 8:45 am]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated February 4, 2004, and published in the **Federal Register** on February 18, 2004, (69 FR 7655), Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50619, made application by renewal to the Drug